| Brandon Donald Bryan, CRNA | |
|
401 E Vaughn Ave, Ruston, LA 71270-5950 | |
| (318) 294-1187 | |
| Not Available |
| Full Name | Brandon Donald Bryan |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 17 Years |
| Location | 401 E Vaughn Ave, Ruston, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609032481 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | RN107925 AP05353 (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northern Louisiana Medical Center | Ruston, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Arena Anesthesia Llc | 4385795319 | 13 |
| Jackson Parish Hospital | 9335048081 | 11 |
News Archive
Enzo Biochem, Inc. today said that its Life Sciences subsidiary will release a new catalog dealing with "Epigenetics & Chromatin Modification" at the Society for Neuroscience's, Neuroscience 2009 conference, beginning October 17, 2009, in Chicago, Illinois.
Lack of exercise or physical activity is estimated to cause as many deaths each year as smoking. Current guidelines recommend at least 150 minutes a week of moderate intensity physical activity, or 75 minutes a week of vigorous-intensity aerobic physical activity (or a combination of the two), and muscle-strengthening exercises two or more days a week.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
Nearly the entire staff of the Pennsylvania Health Care Cost Containment Council has been let go due to a political disagreement between Gov. Ed Rendell (D) and state Senate Republicans over whether a bill to reauthorize the council should also include an extension of a malpractice insurance subsidy for physicians, the Philadelphia Inquirer reports (Goldstein, Philadelphia Inquirer, 7/2).
› Verified 1 days ago
| Entity Name | Jackson Parish Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093793408 PECOS PAC ID: 9335048081 Enrollment ID: O20040102000169 |
News Archive
Enzo Biochem, Inc. today said that its Life Sciences subsidiary will release a new catalog dealing with "Epigenetics & Chromatin Modification" at the Society for Neuroscience's, Neuroscience 2009 conference, beginning October 17, 2009, in Chicago, Illinois.
Lack of exercise or physical activity is estimated to cause as many deaths each year as smoking. Current guidelines recommend at least 150 minutes a week of moderate intensity physical activity, or 75 minutes a week of vigorous-intensity aerobic physical activity (or a combination of the two), and muscle-strengthening exercises two or more days a week.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
Nearly the entire staff of the Pennsylvania Health Care Cost Containment Council has been let go due to a political disagreement between Gov. Ed Rendell (D) and state Senate Republicans over whether a bill to reauthorize the council should also include an extension of a malpractice insurance subsidy for physicians, the Philadelphia Inquirer reports (Goldstein, Philadelphia Inquirer, 7/2).
› Verified 1 days ago
| Entity Name | Arena Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023244779 PECOS PAC ID: 4385795319 Enrollment ID: O20090702000042 |
News Archive
Enzo Biochem, Inc. today said that its Life Sciences subsidiary will release a new catalog dealing with "Epigenetics & Chromatin Modification" at the Society for Neuroscience's, Neuroscience 2009 conference, beginning October 17, 2009, in Chicago, Illinois.
Lack of exercise or physical activity is estimated to cause as many deaths each year as smoking. Current guidelines recommend at least 150 minutes a week of moderate intensity physical activity, or 75 minutes a week of vigorous-intensity aerobic physical activity (or a combination of the two), and muscle-strengthening exercises two or more days a week.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
Nearly the entire staff of the Pennsylvania Health Care Cost Containment Council has been let go due to a political disagreement between Gov. Ed Rendell (D) and state Senate Republicans over whether a bill to reauthorize the council should also include an extension of a malpractice insurance subsidy for physicians, the Philadelphia Inquirer reports (Goldstein, Philadelphia Inquirer, 7/2).
› Verified 1 days ago
| Entity Name | Endoscopy Center Of Monroe |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1417957796 PECOS PAC ID: 3173666120 Enrollment ID: O20100130000072 |
News Archive
Enzo Biochem, Inc. today said that its Life Sciences subsidiary will release a new catalog dealing with "Epigenetics & Chromatin Modification" at the Society for Neuroscience's, Neuroscience 2009 conference, beginning October 17, 2009, in Chicago, Illinois.
Lack of exercise or physical activity is estimated to cause as many deaths each year as smoking. Current guidelines recommend at least 150 minutes a week of moderate intensity physical activity, or 75 minutes a week of vigorous-intensity aerobic physical activity (or a combination of the two), and muscle-strengthening exercises two or more days a week.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
Nearly the entire staff of the Pennsylvania Health Care Cost Containment Council has been let go due to a political disagreement between Gov. Ed Rendell (D) and state Senate Republicans over whether a bill to reauthorize the council should also include an extension of a malpractice insurance subsidy for physicians, the Philadelphia Inquirer reports (Goldstein, Philadelphia Inquirer, 7/2).
› Verified 1 days ago
| Entity Name | Shreveport Sedation Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770083164 PECOS PAC ID: 3173886736 Enrollment ID: O20180412000333 |
News Archive
Enzo Biochem, Inc. today said that its Life Sciences subsidiary will release a new catalog dealing with "Epigenetics & Chromatin Modification" at the Society for Neuroscience's, Neuroscience 2009 conference, beginning October 17, 2009, in Chicago, Illinois.
Lack of exercise or physical activity is estimated to cause as many deaths each year as smoking. Current guidelines recommend at least 150 minutes a week of moderate intensity physical activity, or 75 minutes a week of vigorous-intensity aerobic physical activity (or a combination of the two), and muscle-strengthening exercises two or more days a week.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
Nearly the entire staff of the Pennsylvania Health Care Cost Containment Council has been let go due to a political disagreement between Gov. Ed Rendell (D) and state Senate Republicans over whether a bill to reauthorize the council should also include an extension of a malpractice insurance subsidy for physicians, the Philadelphia Inquirer reports (Goldstein, Philadelphia Inquirer, 7/2).
› Verified 1 days ago
| Entity Name | Anesthesia Dynamics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073001012 PECOS PAC ID: 3779832530 Enrollment ID: O20201020002548 |
News Archive
Enzo Biochem, Inc. today said that its Life Sciences subsidiary will release a new catalog dealing with "Epigenetics & Chromatin Modification" at the Society for Neuroscience's, Neuroscience 2009 conference, beginning October 17, 2009, in Chicago, Illinois.
Lack of exercise or physical activity is estimated to cause as many deaths each year as smoking. Current guidelines recommend at least 150 minutes a week of moderate intensity physical activity, or 75 minutes a week of vigorous-intensity aerobic physical activity (or a combination of the two), and muscle-strengthening exercises two or more days a week.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
Nearly the entire staff of the Pennsylvania Health Care Cost Containment Council has been let go due to a political disagreement between Gov. Ed Rendell (D) and state Senate Republicans over whether a bill to reauthorize the council should also include an extension of a malpractice insurance subsidy for physicians, the Philadelphia Inquirer reports (Goldstein, Philadelphia Inquirer, 7/2).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brandon Donald Bryan, CRNA 135 Creeks Xing, Ruston, LA 71270-1764 Ph: (318) 294-1187 | Brandon Donald Bryan, CRNA 401 E Vaughn Ave, Ruston, LA 71270-5950 Ph: (318) 294-1187 |
News Archive
Enzo Biochem, Inc. today said that its Life Sciences subsidiary will release a new catalog dealing with "Epigenetics & Chromatin Modification" at the Society for Neuroscience's, Neuroscience 2009 conference, beginning October 17, 2009, in Chicago, Illinois.
Lack of exercise or physical activity is estimated to cause as many deaths each year as smoking. Current guidelines recommend at least 150 minutes a week of moderate intensity physical activity, or 75 minutes a week of vigorous-intensity aerobic physical activity (or a combination of the two), and muscle-strengthening exercises two or more days a week.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
Nearly the entire staff of the Pennsylvania Health Care Cost Containment Council has been let go due to a political disagreement between Gov. Ed Rendell (D) and state Senate Republicans over whether a bill to reauthorize the council should also include an extension of a malpractice insurance subsidy for physicians, the Philadelphia Inquirer reports (Goldstein, Philadelphia Inquirer, 7/2).
› Verified 1 days ago
Christopher E Lancaster, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 401 E Vaughn Ave, Ruston, LA 71270 Phone: 318-254-2454 | |
Janie Constance Hill, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 401 E Vaughn Ave, Ruston, LA 71270 Phone: 318-254-2557 | |
Mr. Gregory Allen Strickland Jr., CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 401 E Vaughn Ave, Ruston, LA 71270 Phone: 318-254-2557 | |
Mr. John Harris, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1118 S Farmerville St, Ruston, LA 71270 Phone: 318-232-7700 Fax: 318-232-7148 | |
Mr. Jody D Adams, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1118 S Farmerville St, Ruston, LA 71270 Phone: 318-232-7119 Fax: 318-232-1092 | |
Jennifer Hausgen Lowery, C.R.N.A. Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1118 S Farmerville St, Medical Staff Services, Ruston, LA 71270 Phone: 318-232-1092 | |
Patricia D Volentine, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 401 E Vaughn Ave, Ruston, LA 71270 Phone: 318-254-2100 Fax: 318-254-2557 |